Last updated: August 9, 2026
The National Prescription Opiate Litigation is a multidistrict proceeding in the U.S. District Court for the Northern District of Ohio involving claims that opioid manufacturers, distributors, pharmacies, and related entities helped create or intensify the U.S. opioid crisis. Judge Dan Aaron Polster oversees the MDL.
The litigation has produced major settlements, bellwether verdicts, corporate bankruptcies, and continuing disputes over allocation, releases, and non-settling defendants. It is primarily a mass-tort and public-nuisance proceeding, not a pharmaceutical patent case. The core commercial risk has shifted from trial liability to settlement funding, bankruptcy recoveries, governmental allocation, and residual claims against non-settling parties.
The summary below reflects the principal procedural and financial developments through June 2024.
What is In re: National Prescription Opiate Litigation, MDL 2804?
MDL 2804 consolidates thousands of opioid-related lawsuits filed by states, counties, cities, Native American tribes, hospitals, individuals, and other public and private plaintiffs. The Judicial Panel on Multidistrict Litigation transferred the coordinated proceedings to the Northern District of Ohio in December 2017.[1]
The docket number is 1:17-md-02804. The litigation is commonly called the National Prescription Opiate Litigation or Opioid MDL.
What claims do plaintiffs assert?
Plaintiffs have alleged that opioid manufacturers and distributors:
- Misrepresented opioid addiction risks.
- Promoted opioids for chronic pain without adequate scientific support.
- Failed to monitor suspicious orders.
- Distributed opioids in quantities that exceeded legitimate medical demand.
- Violated federal and state controlled-substance laws.
- Created a public nuisance.
- Caused governmental costs for healthcare, addiction treatment, emergency services, law enforcement, and social programs.
Legal theories vary by plaintiff and defendant. They include negligence, public nuisance, fraud, negligent marketing, unjust enrichment, civil conspiracy, violations of state consumer-protection statutes, and alleged violations of the federal Racketeer Influenced and Corrupt Organizations Act.
The MDL does not resolve every opioid-related claim nationwide. State court actions, bankruptcy proceedings, tribal proceedings, individual injury claims, and claims against non-participating defendants continue outside the central MDL structure.
Who are the principal defendants in MDL 2804?
The defendants fall into four commercial groups.
| Defendant group |
Representative companies |
Core allegations |
| Manufacturers |
Purdue Pharma, Johnson & Johnson/Janssen, Mallinckrodt, Endo, Teva, Allergan/Actavis |
Aggressive promotion, inadequate risk disclosures, and misleading addiction claims |
| Distributors |
McKesson, Cardinal Health, AmerisourceBergen, later Cencora |
Failure to identify, investigate, and report suspicious opioid orders |
| Pharmacies |
CVS, Walgreens, Walmart, Rite Aid, Kroger |
Dispensing and oversight failures |
| Related parties |
Sackler family entities, executives, subsidiaries, and service providers |
Control, enrichment, conspiracy, and settlement-related claims |
Purdue Pharma was the most prominent manufacturer defendant and filed for bankruptcy protection in September 2019. The bankruptcy substantially altered the litigation because Purdue’s estate became subject to an automatic stay while claimants pursued a restructuring-based recovery.
What were the major bellwether cases?
Bellwether cases were selected to test legal theories, evidence, damages, trial management, and settlement value. They were not intended to resolve all claims in the MDL.
County of Summit and County of Cuyahoga v. Purdue Pharma and others
The Ohio county case was among the most important MDL bellwethers. It proceeded against major manufacturers and distributors and was scheduled for trial in 2019. The case settled before a full trial, with the distributors agreeing to pay approximately $260 million to the two counties.[2]
The settlement removed a major trial risk for the distributor defendants but did not establish a binding nationwide finding of liability.
Lake County and Trumbull County v. Purdue Pharma and others
A second Ohio bellwether proceeded to trial in 2021 against major distributors. In November 2021, a federal jury found McKesson, Cardinal Health, and AmerisourceBergen liable for causing a public nuisance in the two Ohio counties.[3]
The case settled before a complete damages phase. The result was significant because it demonstrated that a jury could accept the public-nuisance theory against distributors based on alleged failures in suspicious-order monitoring and distribution controls.
The verdict did not automatically establish liability in other MDL cases. Plaintiffs still face causation, standing, injury, statutory, and damages issues that vary by jurisdiction.
State and tribal proceedings
Several states and tribes pursued parallel or related cases outside the MDL. Oklahoma obtained a $270 million settlement from Purdue in 2019, followed by a $177.5 million settlement with Teva.[4] Oklahoma’s cases were tried separately from the federal MDL and helped establish the valuation range for opioid-related governmental claims.
West Virginia, Washington, New York, California, and other states also reached separate settlements or pursued independent litigation. Tribal governments have negotiated separate allocation and settlement terms in several national agreements.
What major opioid settlements affect MDL 2804?
The largest settlements involve distributors, pharmacies, manufacturers, and Purdue’s bankruptcy estate.
Distributor settlement framework
In July 2021, McKesson, Cardinal Health, and AmerisourceBergen announced a proposed nationwide settlement framework with states and local governments valued at up to approximately $21 billion over 18 years.[5]
The payments were structured over time and conditioned on broad participation by states, municipalities, and other governmental entities. The agreement included injunctive relief involving opioid monitoring, reporting, and distribution controls.
The distributor settlement is commercially important because the three companies handled a large share of U.S. pharmaceutical distribution. It also reduced the likelihood of a sequence of high-value trials against the largest distributors.
Pharmacy settlements
Large pharmacy chains entered separate nationwide settlement agreements:
| Company |
Approximate announced settlement value |
Principal settlement period |
| Walmart |
$3.1 billion |
Multi-year payments |
| CVS |
Approximately $5 billion |
Multi-year payments |
| Walgreens |
Approximately $5.7 billion |
Multi-year payments |
| Kroger |
Approximately $1.2 billion |
Multi-year payments |
Settlement amounts depend on participation, final approvals, payment schedules, and jurisdictional allocation. The agreements also generally include operational controls governing opioid dispensing, suspicious-order review, pharmacist training, and data reporting.
Johnson & Johnson and Janssen
Johnson & Johnson and its Janssen pharmaceutical subsidiary agreed to a nationwide settlement framework valued at approximately $5 billion, subject to participation and allocation requirements.[6] The company separately entered state-specific agreements, and certain states pursued different terms.
The settlement addressed governmental claims concerning opioid marketing and distribution but did not eliminate every potential claim by private individuals or non-participating entities.
Teva
Teva agreed to a nationwide opioid settlement framework valued at approximately $4.25 billion, consisting substantially of cash and in-kind contributions such as medicines for addiction treatment.[7]
The in-kind component affects valuation. Medication donations may reduce governmental treatment costs but do not have the same liquidity as cash for claimants or settlement trusts.
Allergan and other manufacturers
Allergan agreed to an opioid settlement valued at approximately $2.37 billion, including cash and other consideration.[8] Mallinckrodt and Endo pursued bankruptcy restructurings that incorporated opioid liabilities.
The financial recovery from bankrupt manufacturers depends on enterprise value, creditor priority, insurance proceeds, litigation claims, and the treatment of opioid claims under each plan.
What is the Purdue Pharma bankruptcy status?
Purdue filed Chapter 11 in 2019 after facing extensive opioid claims. Its restructuring plan contemplated the dissolution of Purdue and the transfer of assets to a new entity dedicated to public-health and opioid-abatement purposes. The plan also provided broad releases for members of the Sackler family who had not themselves filed for bankruptcy.
In December 2021, the bankruptcy court confirmed the plan. The U.S. Trustee and other parties challenged the nonconsensual releases.
In Harrington v. Purdue Pharma L.P., the U.S. Supreme Court held in June 2024 that the Bankruptcy Code did not authorize the bankruptcy court to release third-party claims against the Sacklers without the claimants’ consent.[9] The Court vacated the confirmation order and remanded the matter.
Why did Harrington v. Purdue Pharma matter?
The decision affected:
- The enforceability of Sackler releases.
- The timing of Purdue’s restructuring.
- The availability of direct claims against Sackler family members.
- The negotiation leverage of governmental and private claimants.
- The ability of mass-tort defendants to use bankruptcy plans to obtain broad third-party protections.
The ruling did not decide whether the Sacklers were liable for opioid-related injuries. It addressed the bankruptcy court’s statutory authority to impose nonconsensual releases.
What is the current litigation posture of MDL 2804?
The MDL has moved from centralized discovery and bellwether development toward settlement administration, remand analysis, bankruptcy coordination, and litigation against non-settling defendants.
The major procedural developments are:
- Early bellwether trials tested public-nuisance and distribution-monitoring theories.
- Large manufacturer, distributor, and pharmacy settlements resolved many governmental claims.
- Purdue’s bankruptcy became a central mechanism for resolving claims against Purdue and related parties.
- The Supreme Court’s 2024 Purdue decision reopened key settlement and release issues.
- Remaining claims continue to vary according to plaintiff type, jurisdiction, defendant, injury theory, and settlement participation.
A settlement does not necessarily terminate every case in MDL 2804. Non-participating plaintiffs may preserve claims, and individual injury claims can raise different causation and damages questions from governmental abatement claims.
How strong are the plaintiffs’ liability theories?
Public nuisance
Public nuisance has been the central theory in many governmental claims. Plaintiffs argue that defendants’ conduct created or substantially contributed to conditions that damaged public health and governmental infrastructure.
The theory has produced mixed results across jurisdictions. Some courts have restricted public-nuisance claims where plaintiffs seek damages for personal injuries or where the alleged conduct occurred outside the forum. Other courts have allowed governmental claims to proceed.
The Ohio bellwether verdict demonstrated that a jury could impose public-nuisance liability on distributors. It did not establish a uniform national rule.
Controlled-substance monitoring
The distributor cases focus on obligations under the Controlled Substances Act and related regulations. Plaintiffs allege that distributors failed to identify, investigate, and report suspicious orders.
Defendants have argued that federal law does not create a private damages action for alleged regulatory violations and that compliance obligations do not establish causation for local opioid injuries. Those defenses remain significant in individual and governmental cases.
Marketing and fraud
Manufacturer claims depend on evidence concerning promotional campaigns, sales-force messaging, risk disclosures, medical education, prescriber targeting, and corporate knowledge of addiction risks.
The evidentiary record includes company documents, regulatory submissions, internal communications, sales data, prescriber information, and expert testimony. The strength of individual claims varies substantially by product, time period, prescriber, patient history, and jurisdiction.
Are there patent, Orange Book, or generic-entry issues?
MDL 2804 is not an Orange Book or Hatch-Waxman patent case. The principal issues are tort liability, public nuisance, statutory compliance, bankruptcy, settlement allocation, and governmental damages.
The litigation does not determine:
- Whether an opioid formulation patent is valid.
- Whether an abbreviated new drug application infringes a patent.
- Whether a generic manufacturer can launch.
- Whether a drug has pediatric or regulatory exclusivity.
- Whether a formulation patent remains enforceable.
Patent rights may affect the commercial value of branded opioid products and settlement negotiations, but patent expiration is not the driver of MDL 2804 liability. Generic competition, abuse-deterrent formulations, opioid labeling, and controlled-substance distribution are relevant market facts rather than the principal causes of action.
What financial exposure did the litigation create?
The aggregate public settlement value has reached tens of billions of dollars when cash, in-kind medicines, bankruptcy contributions, and long-term abatement obligations are included. The headline value overstates immediate liquidity because many agreements pay over 10 to 18 years.
Key exposure factors
- Participation rates by states, municipalities, tribes, and other claimants.
- Allocation formulas based on population, opioid shipments, overdose rates, and treatment needs.
- Bankruptcy recoveries and creditor priority.
- Insurance coverage and exclusions.
- Non-settling defendants’ remaining market share.
- Whether private personal-injury claims are released.
- Compliance costs under injunctive-relief provisions.
- The enforceability of third-party releases.
For distributors and pharmacies, the settlements also impose continuing compliance costs. These include suspicious-order systems, shipment controls, data analytics, reporting, pharmacist oversight, and restrictions on high-risk dispensing patterns.
Which companies remain exposed to opioid litigation?
Exposure differs by defendant.
Manufacturers that settled nationally reduced governmental claim risk but may retain private, state-specific, or non-participating claims. Bankrupt manufacturers face plan-based recovery limits and litigation stays.
Distributors reduced nationwide governmental exposure through settlement agreements but remain subject to compliance obligations and disputes concerning allocation and participation.
Pharmacies face settlement payments, operational controls, state licensing risk, and claims tied to dispensing practices.
Non-settling companies face concentrated trial risk because plaintiffs can use prior verdicts, internal documents, shipment data, and settlement valuations to support remaining claims. Defendants can still challenge causation, standing, damages, statutes of limitation, federal preemption, and the legal sufficiency of public-nuisance theories.
How does MDL 2804 compare with a conventional pharmaceutical mass tort?
MDL 2804 differs from a conventional product-liability case in four ways.
First, many plaintiffs are governmental entities seeking abatement costs rather than individuals seeking compensation for a specific injury.
Second, liability theories focus on aggregate market conduct and distribution systems, not only whether a particular product injured a particular patient.
Third, settlements require participation by large numbers of governmental entities and often use allocation formulas.
Fourth, bankruptcy and third-party releases have a larger role than in ordinary pharmaceutical litigation.
The result is a litigation structure closer to nationwide public-health remediation than to a conventional individual product-liability docket.
Key Takeaways
- MDL 2804 is the federal opioid mass-tort proceeding in the Northern District of Ohio.
- Judge Dan Aaron Polster oversees the litigation.
- The defendants include opioid manufacturers, distributors, pharmacies, and related parties.
- The principal theories are public nuisance, negligent marketing, fraud, statutory violations, and failures to monitor suspicious orders.
- The Lake and Trumbull County bellwether produced a 2021 public-nuisance verdict against the three largest distributors.
- Major settlement frameworks involve distributors, CVS, Walgreens, Walmart, Kroger, Johnson & Johnson, Teva, Allergan, and Purdue-related entities.
- Purdue’s bankruptcy plan was vacated after the Supreme Court’s June 2024 decision in Harrington v. Purdue Pharma.
- The litigation is not a patent or Orange Book dispute.
- Remaining risk depends on claimant participation, settlement releases, bankruptcy recoveries, allocation formulas, and claims against non-settling defendants.
- Long-term settlement payments and compliance obligations create continuing financial exposure even after trial risk declines.
FAQs About MDL 2804
What court handles the National Prescription Opiate Litigation?
The U.S. District Court for the Northern District of Ohio handles MDL 2804 under Judge Dan Aaron Polster.
Did the opioid MDL produce a nationwide trial verdict?
No. The most important federal bellwether verdict came from an Ohio county case against distributors. It did not determine liability for every plaintiff or defendant nationwide.
Can individuals still bring opioid injury claims after the settlements?
Potentially. Settlement releases, bankruptcy injunctions, statutes of limitation, claimant participation, and the specific defendant determine whether an individual claim remains viable.
What did the Supreme Court decide about the Purdue opioid settlement?
In Harrington v. Purdue Pharma, the Court held that the Bankruptcy Code did not authorize a nonconsensual release of claims against the Sackler family in Purdue’s bankruptcy plan.
Do opioid settlements affect generic drug patent rights?
No. The settlements principally resolve tort, public-nuisance, regulatory, and governmental claims. They do not decide patent validity, patent term, Orange Book listing status, or generic launch rights.
References
- Judicial Panel on Multidistrict Litigation. (2017). In re: National Prescription Opiate Litigation, MDL No. 2804, transfer order.
- U.S. District Court for the Northern District of Ohio. (2019). County of Summit v. Purdue Pharma L.P., settlement proceedings in MDL No. 2804.
- U.S. District Court for the Northern District of Ohio. (2021). County of Lake v. Purdue Pharma L.P., MDL No. 2804, bellwether trial proceedings.
- State of Oklahoma v. Purdue Pharma L.P., No. CJ-2017-816, District Court of Cleveland County, Oklahoma.
- McKesson Corporation, Cardinal Health, Inc., and AmerisourceBergen Corporation. (2021). National opioid settlement framework announcement.
- Johnson & Johnson. (2021). Opioid settlement framework with states and local governments.
- Teva Pharmaceutical Industries Ltd. (2022). National opioid settlement framework announcement.
- Allergan plc. (2022). Opioid settlement agreement announcement.
- Supreme Court of the United States. (2024). Harrington v. Purdue Pharma L.P., 603 U.S. 204.
